43 results about "Oral Cavity Squamous Cell Carcinoma" patented technology

The invention belongs to the field of the tumor molecular biological, particularly relating to an oral squamous cell carcinoma diagnostic reagent, kits and medicine. The invention solves the technical problem that the existing medicine and reagent can not early diagnose oral squamous cell carcinoma and can not prevent oral carcinogenesis effectively. The invention oral squamous cell carcinoma diagnostic reagent contains the reagent which can detect expression level of protein RACK1 (activated protein kinase C receptor) and its mRNA content. The oral squamous cell carcinoma kits can be obtained with regular technology. By using the method of screening oral squamous cell carcinoma medicine, the medicine can be screened for preventing oral squamous cell carcinoma medicine, for example: by screen, obtaining effective RACK1 gene and RNA interference molecular, moreover the RNA interference result first reveals the functions of the RNA interference molecular in oral neoplasms apoptosis regulation and oral neoplasms apoptosis treatment, with broad application prospect.

The invention provides a biological marker of oral cavity oropharynx squamous-cell carcinoma and application of the biological marker. The biological marker is GPD1L and / or HIF1 alpha, and especially a combination of the GPD1L and the alpha. According to the invention, by detecting expression levels of the GPD1L and / or the HIF1 alpha, oral cavity oropharynx squamous-cell carcinoma auxiliary diagnosis, oral cavity oropharynx squamous-cell carcinoma patient prognosis, and / or prognosis cervical lymph node metastasis prediction can be performed.

Provided herein are methods for detecting a head and neck cancer of the oral cavity or throat, optionally oral squamous cell carcinoma, comprising executing the step of determining the expression of two or more miRNA in a biological sample obtained from a subject, wherein the two or more miRNA are selected from the group consisting of hsa-let-7a, hsa-miR-16, hsa-miR-21, hsa-miR-451, hsa-miR-486-5pand hsa-miR-92a- 3p, and wherein the level of expression of said two or more niiRNAs in the biological sample relative to the level of expression of said two or more miRNAs in one or more cancer-freereference samples is indicative of the presence of a head and neck cancer of the oral cavity or throat of the subject.

Provides an auxiliary marker for disease identification consisting of decanoylcarnitine, cysteine ​​and bile acids. The present invention also provides a method for constructing a disease identification model, which includes: step 1, obtaining a training case set, and the subjects in the training case set include oral lichen planus patients and oral squamous cell carcinoma patients. In step 2, the serum sample of the subject is collected, and the serum sample is subjected to ultra-high performance liquid chromatography-quadrupole / electrostatic field orbitrap tandem high-resolution mass spectrometry analysis to obtain oral lichen planus and oral squamous cell carcinoma. Multiple differential metabolites; step 3, using variable weight importance ranking and receiver operating characteristic curves to determine decanoylcarnitine, cysteine ​​and bile acids from multiple differential metabolites as a disease discrimination model. The invention provides a disease identification model, which can identify and distinguish oral lichen planus and oral squamous cell carcinoma at an early stage, and has the advantages of minimally invasive and high accuracy.

The invention discloses application of argyreia aceta alkali in biological medicines. The whole herb of argyreia aceta has medicinal value, and argyreia aceta is widely distributed in many places of Guangxi, such as Guigang, Yulin, Fangcheng Gang and Wuming, and is used as a traditional Chinese medicine for treating acute and chronic bronchitis, tuberculosis, liver cirrhosis, nephritis edema, sores and furuncles, acute mastitis, skin eczema, traumatic bleeding and other symptoms. The argyreia aceta alkali is a chemical component separated from argyreia aceta. According to the invention, through the tests for the proliferation inhibition effect of the argyreia aceta alkali on human lung adenocarcinoma cell H2228, human bladder cancer cell T24, human hepatoma carcinoma cell SMMC-7721, humanbreast cancer cell MCF-7, human gastric carcinoma cell MGC-803 and human oral squamous cell carcinoma Tca8113, the argyreia aceta alkali is found to have an excellent inhibiting effect on human bladder cancer cell T24 and human oral squamous cell carcinoma Tca8113 and has no obvious inhibiting effect on other tested tumor cells, so that the argyreia aceta alkali can be used for preparing drugs fortreating bladder cancer or oral squamous cell carcinoma.

The invention discloses a deep learning method for identifying oral squamous cell carcinoma based on visual features, including: 1) establishing a development set and a test set; 2) constructing data training samples; 3) training a target detection network model; 4) passing the The target detection model performs batch initial positioning on the oral photos of the development set, and constructs classification network data samples using the positioned image areas; 5) expands the classification network data samples; 6) DenseNet is used as the backbone network of the classification network, and DenseNet is improved to make the model Focus more on difficult misclassified samples; 7) train the classification network on the expanded samples to obtain an oral squamous cell carcinoma classification network; 8) test the classification network; 9) apply the classification network to classify oral photos. The method has high sensitivity and good specificity for detecting oral squamous cell carcinoma from oral cavity photographs, and is suitable for detection and screening of various oral squamous cell carcinomas.

The invention provides a reagent kit for diagnosing oral squamous cell carcinoma. The reagent kit comprises specific antibodies for detecting HOXA10, specific antibodies for detecting HOXA11, specific antibodies for detecting HOXC6 or compositions with more than one or two optional specific antibodies for detecting the expression quantities of HOXC8. The reagent kit has the advantages that sequencing results for mRNA [messenger RNA (ribonucleic acid)] of the oral squamous cell carcinoma and normal oral tissues in TCGA (the cancer genome atlas) databases are statistically analyzed, data of 32 cases of normal oral tissues and 341 cases of oral squamous cell carcinoma tissues are incorporated, obvious difference of expression of partial genes in HOX families in the oral squamous cell carcinoma and the normal tissues is discovered, and accordingly the reagent kit is suitable to be applied to diagnosing the oral squamous cell carcinoma; expression of genes in the HOX families is detected in oral squamous cell carcinoma tissue pathological sections by the aid of immunohistochemical processes, and accordingly positive expression of the genes in the oral squamous cell carcinoma and application values of the genes in diagnosis can be determined.

The invention discloses application of a molecular marker STAC2 to oral squamous cell carcinoma. Experimental results show that STAC2 is highly expressed in a patient with oral squamous cell carcinoma; and a STAC2-specific siRNA for silencing STAC2 so as to reduce expression of STAC2, so proliferation of oral squamous cell carcinoma is inhibited. Thus, STAC2 can be applied to research on the pathogenesis of oral squamous cell carcinoma and is applicable as a molecular target to clinical diagnosis and treatment of oral squamous cell carcinoma.